Quote | Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)
Last: | $8.34 |
---|---|
Change Percent: | -3.47% |
Open: | $8.73 |
Close: | $8.64 |
High: | $8.79 |
Low: | $8.28 |
Volume: | 1,130,267 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)
2024-07-12 06:40:49 ET Summary Maravai LifeSciences Holdings, Inc. develops drug therapies, diagnostics, and vaccines for global biopharmaceutical companies. Recent sales momentum shows potential sales growth to $300-350 million in FY'25 and FY'26. Despite normalization of sal...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
Message Board Posts | Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)
Subject | By | Source | When |
---|---|---|---|
Maravai LifeSciences stock price target raised to $50 | crudeoil24 | investorshub | 03/03/2021 1:46:42 PM |
Maravai LifeSciences shares are trading higher after the | crudeoil24 | investorshub | 03/03/2021 1:46:22 PM |
Maravai LifeSciences Holdings, Inc. is a life sciences | crudeoil24 | investorshub | 03/03/2021 1:45:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...
2024-05-29 15:15:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MRVI on May 29, 2024 01:35PM ET. The previous analyst recommendation was Outperform. MRVI was trading at $8.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...